
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp demonstrated robust financial growth, with the burn care franchise increasing by 22% year-over-year to $39.9 million in FY2024, a positive indicator of market demand. The company has strategically expanded its burn care salesforce, which is projected to drive high-single-digit growth in 2025, alongside significant contributions from new product launches such as NexoBrid and MACI arthroscopic. Furthermore, Vericel's management guidance anticipates a gross margin of approximately 73-74% and a continuing upward trajectory in revenue, projecting growth rates of 20-23% for 2025, which positions the company favorably for sustained financial performance.
Bears say
Vericel Corp's financial outlook appears negative due to multiple factors, including a lower than expected revenue in January, particularly regarding its CNS and NexoBrid products, which deviated from projections. The company experienced a top-line miss in the fourth quarter, reporting $75.4 million, which fell short of earlier estimates of $77.9 million, underscoring ongoing performance challenges. Additionally, risks related to potential recession impacts, competitive dynamics affecting key products, and operational disruptions—particularly in the launch of NexoBrid and MACI—further contribute to a pessimistic view of future growth prospects.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares